company-logoInvizyne Technologies Inc. Common Stock$16.50
%
Analyst Rating: Hold

Stock Details

CEO

Michael Heltzen

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

29

Address

750 Royal Oaks Drive, Monrovia, NV, 91016

Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Invizyne Technologies Inc. Common Stock  $16.50

EPS

Revenue

Institutional Holder

Congress Tracker 

Insider Trading of Key Employees

Financial News: IZTC